Yet Another Sustained-Delivery Anti-VEGF Drug Ready For Phase 2

A report at the Hawaiian Eye & Retina 2019 conference revealed another sustained-delivery drug, GB-102, for treatment of wet age-related macular degeneration (AMD).  Graybug Vision’s ADAGIO study has now provided evidence that GB-102 can continuously inhibit activity of VEGF for several months. The treatment was well-tolerated in the study and found to be free of dose limiting toxicities, drug-related serious adverse events, or inflammation.

88% and 68% percent of evaluable study subjects were maintained on only a single dose of GB-102 at 3 and 6 months respectively. Currently, patients with wet AMD require intravitreal injections every 6 to 8 weeks. Graybug Vision’s Phase 2b study of GB-102, is expected to begin enrollment in 2019.

This is the second anti-VEGF drug in as many months designed to increase the time between injections. Read about all ongoing research for wet AMD treatment.

Source: Business Wire